Martin Marino Purchases 52,500 Shares of Microbix Biosystems (TSE:MBX) Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino acquired 52,500 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was purchased at an average price of C$0.24 per share, with a total value of C$12,600.00. Following the acquisition, the director owned 1,744,167 shares of the company’s stock, valued at approximately C$418,600.08. This trade represents a 3.10% increase in their ownership of the stock.

Martin Marino also recently made the following trade(s):

• On Monday, December 22nd, Martin Marino bought 100,000 shares of Microbix Biosystems stock. The shares were bought at an average cost of C$0.23 per share, with a total value of C$23,000.00.

Microbix Biosystems Stock Up 2.3%

Shares of Microbix Biosystems stock traded up C$0.01 during midday trading on Friday, hitting C$0.22. The company’s stock had a trading volume of 35,000 shares, compared to its average volume of 107,382. The stock has a 50-day simple moving average of C$0.24 and a 200-day simple moving average of C$0.25. The firm has a market capitalization of C$30.54 million, a P/E ratio of -13.75 and a beta of 0.03. The company has a quick ratio of 5.57, a current ratio of 7.15 and a debt-to-equity ratio of 22.61. Microbix Biosystems Inc. has a 1-year low of C$0.21 and a 1-year high of C$0.55.

Microbix Biosystems (TSE:MBX) last issued its earnings results on Thursday, December 18th. The company reported C($0.01) earnings per share for the quarter. Microbix Biosystems had a net margin of 13.86% and a return on equity of 12.65%. The business had revenue of C$3.74 million during the quarter. As a group, sell-side analysts expect that Microbix Biosystems Inc. will post 0.02 earnings per share for the current year.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.